J&J’s Darzalex Scores Again In Frontline Myeloma

But Challenger Arriving In 2020

Janssen’s hemato-oncology success rolls on with impressive new overall survival data

Johnson_and_Johnson — CAR-T candidate JNJ-4528 is set to add to Darzalex and Imbruvica in J&J's hemato-oncology franchise

Johnson & Johnson’s multiple myeloma blockbuster Darzalex is on a roll, and has just added to its success with some remarkable overall survival (OS) data.

Results from the Phase III ALCYONE study of Darzalex (daratumumab) with bortezomib, melphalan and prednisone (D-VMP) show adding the drug...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Former Moderna Exec Launches Company Focused On mRNA Despite HHS Funding Cuts

21 Aug 2025

• By David Wild

Emerging Company Profile: Axelyf raises $2.6m seed round for lipid nanoparticle delivery platform on heels of end to US federal support for mRNA vaccines.

Nicox Plots US Submission After Another Phase III Glaucoma Win

21 Aug 2025

• By Kevin Grogan

The France-headquartered firm’s eye drop has demonstrated efficacy in a second pivotal trial.

Rocket’s Warp Drive Back Online As FDA Lifts Danon Gene Therapy Hold

20 Aug 2025

• By Alaric DeArment

The company took a prophylactic C3 inhibitor out of the immunomodulatory regimen used in its Phase II study of RP-A501, lowered the dose and adjusted its use of eculizumab.